We are pleased to announce that Sachi Bioworks has won Phase II NASA SBIR award to advance it’s best-in-class and first-in-class immunotherapy molecules for reversing immune dysfunction, towards clinical translation.
In Sachi’s successful Phase I demonstration, 17 immune targets were tested for reversing immune dysfunction during spaceflight missions, including both up and downregulation of targets using immunomodulatory molecules (loss-of-function and gain-of-function using Sachi molecules), rapid identification and testing of lead molecules for each target (combing state-of-the-art bioinformatics and proprietary AI platform), testing of each target using diverse pool of donor-derived immune cells, identification of best therapeutic target and immunotherapy for further testing, and in vivo reversal of radiation-induced immunosuppression in pre-clinical trial. This demonstrated the power of the Sachi platform in accelerating therapeutic discovery, along with safety, efficacy, and ease of administration of Sachi immunotherapeutic molecules.
Sachi will be advancing lead candidates for neurotherapeutic applications for reversal of space radiation-induced neurodegeneration. Sachi’s commercialization objective also includes translating the immunotherapies developed for a range of terrestrial and space-medicine applications such as safely reversing immunosuppression in cancer radiotherapy and chemotherapy patients and immunocompromised individuals, testing and translation of immunotherapies shown to safely and reversibly boosting host-immune defense as pathogen-agnostic broad-spectrum anti-infectives (anti-viral, anti-bacterial, anti-fungal), as pandemic countermeasures. Sachi will use safety-toxicity studies in small and large animals, efficacy, and a team of regulatory consultants and experts with several decades of experience in the field, to help advance the molecules towards human clinical studies and market adoption.